Biotech stocks have plummeted in 2021 after soaring last year amid excitement over the development of a COVID-19 vaccine, taking a toll on some hedge funds.
The sector is being countered by concerns Congress will move to cover up drug pricing and the rise of early-stage biotech stocks like IPO market boom.
Percept Advisors, a popular biotech hedge fund that manages about $9 billion, has lost about 30% this year through November in its main fund, investors say, investors say. know. A hedge fund managed by OrbiMed Partners, which invests more than $18 billion in healthcare in the public and private markets, has lost more than 40% in the year to November, people familiar with the matter said. fund said. Both funds have made great returns over the past two years.
Meanwhile, a hedge fund run by San Francisco-based Logos Capital, which manages about $1.4 billion, is down more than 25% over the period, others said. The cormorant asset manager lost 10% in November alone, adding to its double-digit loss earlier in the year.
“It has been a very challenging year,” said Bihua Chen, founder of Cormorant, which focuses on small biotech companies.
Also popular on WSJ.com:
Source link Biotech Roadmap in 2021 Has Led to Some Huge Hedge Fund Losses